Legal and compliance teams have to serve as sentinels sizing up potential legal exposure points without turning into needlers who only slow down clinical innovation.
U.S. healthcare is in the throes of an affordability crisis. The good news is that healthcare leaders have all the evidence, tools and expertise needed to keep the predicament from becoming a plight. Can they marshal the will to wield those weapons toward that end?
He’s picking Nicole B. Saphier, MD, a board-certified breast specialist with Memorial Sloan Kettering Cancer Center and Fox News contributor, to fill the key role.
Mina Chung, MD, who just concluded a one-year term as Heart Rhythm Society's president, spoke to Cardiovascular Business about successes from the past year as well as her goals for the future.
Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.
Corresponding with the change, the Chicago-based imaging manufacturer is combing two of its radiology-related business lines into a new segment worth $14.6 billion.
The new Class I recall, which includes more than 1.4 million devices, is related to an issue first announced back in 2024. Updating the software should address the issue going forward, though some patients may still require an early replacement.
Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.
Legal and compliance teams have to serve as sentinels sizing up potential legal exposure points without turning into needlers who only slow down clinical innovation.
U.S. healthcare is in the throes of an affordability crisis. The good news is that healthcare leaders have all the evidence, tools and expertise needed to keep the predicament from becoming a plight. Can they marshal the will to wield those weapons toward that end?
